Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Maybe that's him sitting at the bid with 60K to go out of the 80K at $2.80.
My full book on NSDQ and EDGX show there is hardly anything until $2.94.
A 2,000 share order at market would take us all the way to $2.94
nice - 80K at the bid for $2.80
Full book on NSDQ shows about 30K for sale up to 2.98... and full book on EDGX EDGA and BATS show another 20K for sale up to 2.98.
I was going to post early this A.M. that I see a $2.98 close... and even with 50K in the way... I'll still call for a 2.98 close.
We have a steady buyer in the background... but he's wiley and not in a hurry... in fact I think he'll be around for the next 2 weeks.
Just a WILD ASS GUESS!!!
That's a really sweet deal for CNAT - didn't know there was that kind of money in liver disease... notice it's still in phase 2.
Most partnerships follow patterns that are not hard to estimate... you figure out how big the pie is likely to be and then split it according to accepted norms... but PODRAS makes this partnership rather opaque.
My guess is that Rexista XR alone would have been a $400 million total package, and a "balanced deal" rather than "front loaded" or "back loaded" deal - that is, about 10% or $40 million up front - 10% to 15% or $40 to $60 million on FDA approval... + milestone payments of 10% per Billion $ in aggregate sales for up to $3 billion, or a total of $400 million + 20% royalties up to $3 billion and 25% thereafter.
Oxtenda however complicates the situation, it's hard to know what it will do market wise... it may blow Perdue out of the water or it may fizzle out.. no-one really knows so I think it will perhaps be a "back loaded" deal which is fair to all when there are wild unknowns.
I can't imagine the partnership not incorporating both products as it would become awfully sloppy, but my wild-ass-guess is:
A back loaded total package of $1 Billion with the same figures as Rexista XR alone initially... but a milestone payment of $100 million on FDA approval of Oxtenda with milestone payments of $100 million per $1 Billion in aggregate sales up to $5 Billion which would equate to a total $500 million more + 20% royalty up to $5 billion and 25% there after... plus partner picks up all development costs... or to put it more simply, 30% royalty up to $5 billion and 25% thereafter.
the partnership when announced will be huge
All the I Hub Message Boards that I tried have been down all day.
They are still not up to par.
it has already gone generic so commercialization could be upon approval/partnership
March 27, 2008 note the date - this has been a long time coming.
http://www.intellipharmaceutics.com/releasedetail.cfm?ReleaseID=439215
The initial pilot clinical trial was designed to compare the pharmacokinetic characteristics of the IntelliPharmaCeutics ReXistaTM oxycodone product, in a once-a-day 40mg dosage format, with a currently marketed branded oxycodone product, Purdue Pharma’s Oxycontin®, in a twice-a-day 20mg dosage format, under fasted conditions.
The pilot clinical trial produced the following results:
- The ReXistaTM product demonstrated sustained release pharmacokinetic activity, with blood plasma concentrations at clinically significant levels over a 24 hour period.
- The bioavailability of a single dose of the ReXistaTM product, as measured by Cmax and AUC, was comparable to that of two doses of Oxycontin® dosed at 12 hour intervals. Both Cmax and AUC were in the 80% - 125% range as compared to Oxycontin®, demonstrating effective bioequivalence with the branded product.
Collegium Xtampza Needs to be administered with Food, and is not bio-equivalent to Oxycontin.
With 4 players the potential is 25% assuming equally distributed. But, we know that won't be the case??? so it's hard to say how things will turn out for Rexista.
Glucophage XR has a huge $2.4 Billion market.
Big... big market - but there are approximately 15 distributors for that one... so not really much to be gained there... as most sell it for peanuts.
https://www.goodrx.com/metformin-er-glucophage-xr
What do you all think would happen to the stock price if we saw INSIDERS BUYING IPCI Shares in the next couple weeks
I give up - numbers help!!!
I know there are 5 manufacturers/distributors for Focalin XR including Novartis.
I've been spinning around and around on the Drugs@FDA site trying to determine how many manufacturers/distributors there will be for Seroquel XR.
I know AstraZeneca and Accord so far, but can't find the page that lists all others that have received tentative approval.
A little help on that numbers.
One thing you did forget about however are the one time milestone payments.
shall be payable on a quarterly basis and within thirty (30) days of the end of each applicable calendar quarter.
With respect to 180-day generic drug exclusivity, we note that Par was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Dexmethylphenidate Hydrochloride Extended-Release Capsules, 25 mg and 35 mg. Therefore, with this approval, Par is eligible for 180 days of generic drug exclusivity for Dexmethylphenidate Hydrochloride Extended-Release Capsules, 25 mg and 35 mg
is that you at 2.70?
Why put upfront money on the table now if the revenues are not going to be flowing for a while?
Does that mean, their filed NDA for Rexista excluding PODRAS is not on "fast track"?
for any Generic of the Brand Product
Regardless of whether we get a PR or not... PAR's next royalty payment, which IPCI should receive around early February, will be for 3 months of the 15 and 30mg doses AND one month of all 6, or possibly 8 doses... and although it's only one month it should be a GOOD MONTH as PAR will be "shelf stocking" the other doses that month, thereby resulting in an inflated quantity... I hope!!!
Anyway... it should help in keeping the wolf at bay!!!
why the company hasn't put out a PR yet is disturbing, but its possible IPCI wasn't told yet
They do now - 8 doses - approved November 30, 2016 - ANDA # 202842
Thanxs to grill4thrills who made us aware of it -
http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202842
And... we are going to get royalties on all doses - so for all intent and purpose - Our Focalin XR has finally ARRIVED!!!
If IPCI was getting 1/2 million $ per quarter in royalty payments on 2 doses, they should now get ~ 1-1/2 million $ on 6 doses (or perhaps even more on 8 doses)... and their first quarter - end of February 2017 should include one month (December), or 1/3 of the additional royalty payments.
2nd quarter (May 2017) should include a full quarter royalty payment from PAR... or approx $1.5 to $2 million.
Thanxs for your remarkable DD numbers... you're invaluable to this board.
It affects absolutely nothing other than matters related to Focalin XR - which will probably "eventually" be partnered with Mallinckrodt also... as we know they don't have Focalin XR in their pipeline and I'm sure they would like to.
I can see a potentially healthy symbiotic relationship between Mallinckrodt and IPCI down the road... for both the existing IPCI generic pipeline and other ANDAs to come developed specifically for MKD... and an eventual buyout of the complete ANDA line in the future.
I had asked for Penna’s email on this board
Going by patent #
078908 - Teva - all doses except 25 30 and 35
202731 - TEVA - 30
078992 - IPCI - 15 and 30
202842 - PAR - All doses (8) -- only mfg. with 25 and 35 generic approved
Teva's 15 mg was submitted before IPCI but perhaps had an error that allowed IPCI to become 1st to file.
It appears that PAR submitted all doses same time although relatively later than TEVA and IPCI - so their interest was all along only in the 15 and 30 mg 180 day exclusivity.
I imagine down the road - sometime - all doses will have FDA approval and they can partner Focalin XR with Mallinckrodt.
SOB - looks like PAR has gotten FDA approval on all doses of Focalin XR, including the 15mg and 30mg which IPCI has approval on... now we know why the other IPCI doses were not approved... they were probably working on their own ANDA all along.
The agreement with PAR was not mutually exclusise and both PAR and IPCI could manufacture for and distribute other's Focalin XR.
We don't even know if PAR has submitted IPCI's other doses for approval... or if they can be legally made to seek approval even though they now have their own to sell... seems like a really dirty trick to me.
Number of IPCI shares outstanding as of August 31, 2016 = 29 million - fully diluted = 37.4 million
If/when fully diluted @ above $3.55 p/s the 8.4 million option, warrants & convertible debt would add $25,849,000 in cash or an average of $3.07 per share.
October 2016 IPCI Slide PRESENTATION
October 2016 IPCI Slide Presentation - Slide 24 - Oustanding Shares Info
October 2016 IPCI's Full Pipeline
The above info has now been placed in the intro section of the IPCI web page (just above the message section) for ready reference as needed.
Some have argued the patent is baked in
what makes just 100,000 shares on 6 mil.
It's dated 11/30/2016 - so if it was Odidi selling yesterday, then that would explain the constant downward pressure.
Assuming that was the constant pressure... we fared quite well... and I'm delighted as to how well we held up!!!
Thanxs cysonic, you made my day.
Man I got the hell beat out of me in all my Biotech holdings today... but I guess it could have been worse... I could have been holding HTBX.
Sorry Fabius... I believe it was you that was into that one... sorry for your loss of money, and the loss of a possible immuno-oncology solution to Superficial Bladder Cancer.
I don't know if you're seeing it - but my Full Book NASDQ shows 7K shares on the ask at $2.81 being covered by the 1K on the ask at $2.80 showing.
ImpactTrader - FYI - you are apparently clicking on the "Post New Msg" link and therefore leaving it up to us to guess as to who you are responding to.
If you click on the "Public Reply" link instead, all the way to the left... it will indicate in your post who the message is directly meant for... and save us some guessing work.
You're welcome.
The other half of Pregabalin market is Diabetic Peripheral Neuropathy. There is also epilepsy. If IPCI wants to target the other indications, IPCI might have to do a Phase 3 for each indication.
I don't think it's genuine selling going on.
I think it's perhaps a handful of manipulators selling back and forth to each other but never really letting go of the shares from amongst themselves.
Look what we knew to be a genuine buy for 10K at 2.83 did - it literally stopped the price slide for several HOURS, because to get past those 10K shares, they would have to sacrifice those 10K shares - so they did not sell to him as long as he was there... but eventually there actually were sales, from genuine sellers, that totaled 10K, and once Impact was filled... there was a flood of selling back and forth to each other again.
I think it's mostly manipulation we're seeing, and not genuine selling... but it's all guesswork on my part.
I believe Odidi has a vision and it goes beyond what they presently have showing.
All of this concentrating on Rexista has fogged the fact that Regabatin for example may well be bigger than Rexista... but additionally... they actually have multiple delivery platforms, most of which I believe are valuable but have not yet been explored because of lack of funds and manpower.
PODRAS will never be incorporated into over the counter pills - it's simply not cost effective... but a platform that would take an ibuprofen tablet and turn it into 1X a day so that it can compete against 2x a day Aleve would probably bring in say $100 million a year in royalties and another $10 to $20 million in cost plus manufacturing... and that is just one example of what IPCI still needs to explore.
I believe once IPCI gets to say $10 - $12 a share... a raise of perhaps $100 million will take place which will allow them to bring in talent that thinks out of the box to explore and maximize the potential of their complete extended release line.
As another example how about medications on those strips like listerine uses that stick to the roof of your mouth - for people who can't swallow pills.
I also think they still want to become a manufacturing force utilizing their platforms to improve other peoples indications... but most of all...
So they will need funds to hire talent to explore all the possibilities... and to build the manufacturing facilities for those possibilities.